Avanza Fonder AB Invests $4.01 Million in Kenvue Inc. (NYSE:KVUE)

Avanza Fonder AB acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 187,780 shares of the company’s stock, valued at approximately $4,009,000.

Several other large investors also recently bought and sold shares of the business. FMR LLC raised its stake in Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after buying an additional 3,075,019 shares during the last quarter. State Street Corp grew its holdings in shares of Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA increased its position in Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares during the last quarter. Geode Capital Management LLC increased its position in Kenvue by 0.9% during the third quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock valued at $1,029,810,000 after acquiring an additional 399,846 shares during the last quarter. Finally, Harris Associates L P lifted its holdings in Kenvue by 7.5% in the third quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock valued at $727,658,000 after acquiring an additional 2,186,114 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Down 0.4 %

Shares of KVUE stock opened at $21.11 on Friday. The stock has a fifty day simple moving average of $22.42 and a two-hundred day simple moving average of $21.66. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The firm has a market capitalization of $40.46 billion, a PE ratio of 38.37, a PEG ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter last year, the business posted $0.31 earnings per share. The firm’s revenue was down .4% on a year-over-year basis. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.89%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Barclays reduced their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday. Bank of America upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Jefferies Financial Group assumed coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective for the company. Finally, Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $21.00 to $26.00 in a report on Monday, January 6th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.